Global Disease-Modifying Antirheumatic Drug Market Growth 2024-2030
The report requires updating with new data and is sent in 48 hours after order is placed.
According to our LPI (LP Information) latest study, the global Disease-Modifying Antirheumatic Drug market size was valued at US$ million in 2023. With growing demand in downstream market, the Disease-Modifying Antirheumatic Drug is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during review period.
The research report highlights the growth potential of the global Disease-Modifying Antirheumatic Drug market. Disease-Modifying Antirheumatic Drug are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Disease-Modifying Antirheumatic Drug. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Disease-Modifying Antirheumatic Drug market.
It refers to drugs that can treat rheumatism, such as non-steroidal anti-inflammatory drugs, steroidal anti-inflammatory drugs, etc.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Key Features:
The report on Disease-Modifying Antirheumatic Drug market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the Disease-Modifying Antirheumatic Drug market. It may include historical data, market segmentation by Type (e.g., Non-Steroidal Anti-Inflammatory Drugs, Steroidal Anti-Inflammatory Drugs), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Disease-Modifying Antirheumatic Drug market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Disease-Modifying Antirheumatic Drug market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Disease-Modifying Antirheumatic Drug industry. This include advancements in Disease-Modifying Antirheumatic Drug technology, Disease-Modifying Antirheumatic Drug new entrants, Disease-Modifying Antirheumatic Drug new investment, and other innovations that are shaping the future of Disease-Modifying Antirheumatic Drug.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Disease-Modifying Antirheumatic Drug market. It includes factors influencing customer ' purchasing decisions, preferences for Disease-Modifying Antirheumatic Drug product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Disease-Modifying Antirheumatic Drug market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Disease-Modifying Antirheumatic Drug market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Disease-Modifying Antirheumatic Drug market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Disease-Modifying Antirheumatic Drug industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Disease-Modifying Antirheumatic Drug market.
Market Segmentation:
Disease-Modifying Antirheumatic Drug market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Segmentation by type
What is the 10-year outlook for the global Disease-Modifying Antirheumatic Drug market?
What factors are driving Disease-Modifying Antirheumatic Drug market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Disease-Modifying Antirheumatic Drug market opportunities vary by end market size?
How does Disease-Modifying Antirheumatic Drug break out type, application?
According to our LPI (LP Information) latest study, the global Disease-Modifying Antirheumatic Drug market size was valued at US$ million in 2023. With growing demand in downstream market, the Disease-Modifying Antirheumatic Drug is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during review period.
The research report highlights the growth potential of the global Disease-Modifying Antirheumatic Drug market. Disease-Modifying Antirheumatic Drug are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Disease-Modifying Antirheumatic Drug. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Disease-Modifying Antirheumatic Drug market.
It refers to drugs that can treat rheumatism, such as non-steroidal anti-inflammatory drugs, steroidal anti-inflammatory drugs, etc.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Key Features:
The report on Disease-Modifying Antirheumatic Drug market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the Disease-Modifying Antirheumatic Drug market. It may include historical data, market segmentation by Type (e.g., Non-Steroidal Anti-Inflammatory Drugs, Steroidal Anti-Inflammatory Drugs), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Disease-Modifying Antirheumatic Drug market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Disease-Modifying Antirheumatic Drug market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Disease-Modifying Antirheumatic Drug industry. This include advancements in Disease-Modifying Antirheumatic Drug technology, Disease-Modifying Antirheumatic Drug new entrants, Disease-Modifying Antirheumatic Drug new investment, and other innovations that are shaping the future of Disease-Modifying Antirheumatic Drug.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Disease-Modifying Antirheumatic Drug market. It includes factors influencing customer ' purchasing decisions, preferences for Disease-Modifying Antirheumatic Drug product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Disease-Modifying Antirheumatic Drug market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Disease-Modifying Antirheumatic Drug market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Disease-Modifying Antirheumatic Drug market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Disease-Modifying Antirheumatic Drug industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Disease-Modifying Antirheumatic Drug market.
Market Segmentation:
Disease-Modifying Antirheumatic Drug market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Segmentation by type
- Non-Steroidal Anti-Inflammatory Drugs
- Steroidal Anti-Inflammatory Drugs
- Slow Acting Drug
- Immunological Preparation
- Pharmaceutical Industry
- Hospital and Clinic
- Other
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- AbbVie
- Amgen
- Pfizer
- Roche Holding AG
- Novartis International AG
- Johnson & Johnson
- Bristol-Myers Squibb
- Merck
- UCB S.A.
- Eli Lilly and Company
What is the 10-year outlook for the global Disease-Modifying Antirheumatic Drug market?
What factors are driving Disease-Modifying Antirheumatic Drug market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Disease-Modifying Antirheumatic Drug market opportunities vary by end market size?
How does Disease-Modifying Antirheumatic Drug break out type, application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Disease-Modifying Antirheumatic Drug Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Disease-Modifying Antirheumatic Drug by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Disease-Modifying Antirheumatic Drug by Country/Region, 2019, 2023 & 2030
2.2 Disease-Modifying Antirheumatic Drug Segment by Type
2.2.1 Non-Steroidal Anti-Inflammatory Drugs
2.2.2 Steroidal Anti-Inflammatory Drugs
2.2.3 Slow Acting Drug
2.2.4 Immunological Preparation
2.3 Disease-Modifying Antirheumatic Drug Sales by Type
2.3.1 Global Disease-Modifying Antirheumatic Drug Sales Market Share by Type (2019-2024)
2.3.2 Global Disease-Modifying Antirheumatic Drug Revenue and Market Share by Type (2019-2024)
2.3.3 Global Disease-Modifying Antirheumatic Drug Sale Price by Type (2019-2024)
2.4 Disease-Modifying Antirheumatic Drug Segment by Application
2.4.1 Pharmaceutical Industry
2.4.2 Hospital and Clinic
2.4.3 Other
2.5 Disease-Modifying Antirheumatic Drug Sales by Application
2.5.1 Global Disease-Modifying Antirheumatic Drug Sale Market Share by Application (2019-2024)
2.5.2 Global Disease-Modifying Antirheumatic Drug Revenue and Market Share by Application (2019-2024)
2.5.3 Global Disease-Modifying Antirheumatic Drug Sale Price by Application (2019-2024)
3 GLOBAL DISEASE-MODIFYING ANTIRHEUMATIC DRUG BY COMPANY
3.1 Global Disease-Modifying Antirheumatic Drug Breakdown Data by Company
3.1.1 Global Disease-Modifying Antirheumatic Drug Annual Sales by Company (2019-2024)
3.1.2 Global Disease-Modifying Antirheumatic Drug Sales Market Share by Company (2019-2024)
3.2 Global Disease-Modifying Antirheumatic Drug Annual Revenue by Company (2019-2024)
3.2.1 Global Disease-Modifying Antirheumatic Drug Revenue by Company (2019-2024)
3.2.2 Global Disease-Modifying Antirheumatic Drug Revenue Market Share by Company (2019-2024)
3.3 Global Disease-Modifying Antirheumatic Drug Sale Price by Company
3.4 Key Manufacturers Disease-Modifying Antirheumatic Drug Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Disease-Modifying Antirheumatic Drug Product Location Distribution
3.4.2 Players Disease-Modifying Antirheumatic Drug Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR DISEASE-MODIFYING ANTIRHEUMATIC DRUG BY GEOGRAPHIC REGION
4.1 World Historic Disease-Modifying Antirheumatic Drug Market Size by Geographic Region (2019-2024)
4.1.1 Global Disease-Modifying Antirheumatic Drug Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Disease-Modifying Antirheumatic Drug Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Disease-Modifying Antirheumatic Drug Market Size by Country/Region (2019-2024)
4.2.1 Global Disease-Modifying Antirheumatic Drug Annual Sales by Country/Region (2019-2024)
4.2.2 Global Disease-Modifying Antirheumatic Drug Annual Revenue by Country/Region (2019-2024)
4.3 Americas Disease-Modifying Antirheumatic Drug Sales Growth
4.4 APAC Disease-Modifying Antirheumatic Drug Sales Growth
4.5 Europe Disease-Modifying Antirheumatic Drug Sales Growth
4.6 Middle East & Africa Disease-Modifying Antirheumatic Drug Sales Growth
5 AMERICAS
5.1 Americas Disease-Modifying Antirheumatic Drug Sales by Country
5.1.1 Americas Disease-Modifying Antirheumatic Drug Sales by Country (2019-2024)
5.1.2 Americas Disease-Modifying Antirheumatic Drug Revenue by Country (2019-2024)
5.2 Americas Disease-Modifying Antirheumatic Drug Sales by Type
5.3 Americas Disease-Modifying Antirheumatic Drug Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Disease-Modifying Antirheumatic Drug Sales by Region
6.1.1 APAC Disease-Modifying Antirheumatic Drug Sales by Region (2019-2024)
6.1.2 APAC Disease-Modifying Antirheumatic Drug Revenue by Region (2019-2024)
6.2 APAC Disease-Modifying Antirheumatic Drug Sales by Type
6.3 APAC Disease-Modifying Antirheumatic Drug Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Disease-Modifying Antirheumatic Drug by Country
7.1.1 Europe Disease-Modifying Antirheumatic Drug Sales by Country (2019-2024)
7.1.2 Europe Disease-Modifying Antirheumatic Drug Revenue by Country (2019-2024)
7.2 Europe Disease-Modifying Antirheumatic Drug Sales by Type
7.3 Europe Disease-Modifying Antirheumatic Drug Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Disease-Modifying Antirheumatic Drug by Country
8.1.1 Middle East & Africa Disease-Modifying Antirheumatic Drug Sales by Country (2019-2024)
8.1.2 Middle East & Africa Disease-Modifying Antirheumatic Drug Revenue by Country (2019-2024)
8.2 Middle East & Africa Disease-Modifying Antirheumatic Drug Sales by Type
8.3 Middle East & Africa Disease-Modifying Antirheumatic Drug Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Disease-Modifying Antirheumatic Drug
10.3 Manufacturing Process Analysis of Disease-Modifying Antirheumatic Drug
10.4 Industry Chain Structure of Disease-Modifying Antirheumatic Drug
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Disease-Modifying Antirheumatic Drug Distributors
11.3 Disease-Modifying Antirheumatic Drug Customer
12 WORLD FORECAST REVIEW FOR DISEASE-MODIFYING ANTIRHEUMATIC DRUG BY GEOGRAPHIC REGION
12.1 Global Disease-Modifying Antirheumatic Drug Market Size Forecast by Region
12.1.1 Global Disease-Modifying Antirheumatic Drug Forecast by Region (2025-2030)
12.1.2 Global Disease-Modifying Antirheumatic Drug Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Disease-Modifying Antirheumatic Drug Forecast by Type
12.7 Global Disease-Modifying Antirheumatic Drug Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 AbbVie
13.1.1 AbbVie Company Information
13.1.2 AbbVie Disease-Modifying Antirheumatic Drug Product Portfolios and Specifications
13.1.3 AbbVie Disease-Modifying Antirheumatic Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 AbbVie Main Business Overview
13.1.5 AbbVie Latest Developments
13.2 Amgen
13.2.1 Amgen Company Information
13.2.2 Amgen Disease-Modifying Antirheumatic Drug Product Portfolios and Specifications
13.2.3 Amgen Disease-Modifying Antirheumatic Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Amgen Main Business Overview
13.2.5 Amgen Latest Developments
13.3 Pfizer
13.3.1 Pfizer Company Information
13.3.2 Pfizer Disease-Modifying Antirheumatic Drug Product Portfolios and Specifications
13.3.3 Pfizer Disease-Modifying Antirheumatic Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Pfizer Main Business Overview
13.3.5 Pfizer Latest Developments
13.4 Roche Holding AG
13.4.1 Roche Holding AG Company Information
13.4.2 Roche Holding AG Disease-Modifying Antirheumatic Drug Product Portfolios and Specifications
13.4.3 Roche Holding AG Disease-Modifying Antirheumatic Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Roche Holding AG Main Business Overview
13.4.5 Roche Holding AG Latest Developments
13.5 Novartis International AG
13.5.1 Novartis International AG Company Information
13.5.2 Novartis International AG Disease-Modifying Antirheumatic Drug Product Portfolios and Specifications
13.5.3 Novartis International AG Disease-Modifying Antirheumatic Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Novartis International AG Main Business Overview
13.5.5 Novartis International AG Latest Developments
13.6 Johnson & Johnson
13.6.1 Johnson & Johnson Company Information
13.6.2 Johnson & Johnson Disease-Modifying Antirheumatic Drug Product Portfolios and Specifications
13.6.3 Johnson & Johnson Disease-Modifying Antirheumatic Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Johnson & Johnson Main Business Overview
13.6.5 Johnson & Johnson Latest Developments
13.7 Bristol-Myers Squibb
13.7.1 Bristol-Myers Squibb Company Information
13.7.2 Bristol-Myers Squibb Disease-Modifying Antirheumatic Drug Product Portfolios and Specifications
13.7.3 Bristol-Myers Squibb Disease-Modifying Antirheumatic Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 Bristol-Myers Squibb Main Business Overview
13.7.5 Bristol-Myers Squibb Latest Developments
13.8 Merck
13.8.1 Merck Company Information
13.8.2 Merck Disease-Modifying Antirheumatic Drug Product Portfolios and Specifications
13.8.3 Merck Disease-Modifying Antirheumatic Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 Merck Main Business Overview
13.8.5 Merck Latest Developments
13.9 UCB S.A.
13.9.1 UCB S.A. Company Information
13.9.2 UCB S.A. Disease-Modifying Antirheumatic Drug Product Portfolios and Specifications
13.9.3 UCB S.A. Disease-Modifying Antirheumatic Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 UCB S.A. Main Business Overview
13.9.5 UCB S.A. Latest Developments
13.10 Eli Lilly and Company
13.10.1 Eli Lilly and Company Company Information
13.10.2 Eli Lilly and Company Disease-Modifying Antirheumatic Drug Product Portfolios and Specifications
13.10.3 Eli Lilly and Company Disease-Modifying Antirheumatic Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.10.4 Eli Lilly and Company Main Business Overview
13.10.5 Eli Lilly and Company Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Disease-Modifying Antirheumatic Drug Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Disease-Modifying Antirheumatic Drug by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Disease-Modifying Antirheumatic Drug by Country/Region, 2019, 2023 & 2030
2.2 Disease-Modifying Antirheumatic Drug Segment by Type
2.2.1 Non-Steroidal Anti-Inflammatory Drugs
2.2.2 Steroidal Anti-Inflammatory Drugs
2.2.3 Slow Acting Drug
2.2.4 Immunological Preparation
2.3 Disease-Modifying Antirheumatic Drug Sales by Type
2.3.1 Global Disease-Modifying Antirheumatic Drug Sales Market Share by Type (2019-2024)
2.3.2 Global Disease-Modifying Antirheumatic Drug Revenue and Market Share by Type (2019-2024)
2.3.3 Global Disease-Modifying Antirheumatic Drug Sale Price by Type (2019-2024)
2.4 Disease-Modifying Antirheumatic Drug Segment by Application
2.4.1 Pharmaceutical Industry
2.4.2 Hospital and Clinic
2.4.3 Other
2.5 Disease-Modifying Antirheumatic Drug Sales by Application
2.5.1 Global Disease-Modifying Antirheumatic Drug Sale Market Share by Application (2019-2024)
2.5.2 Global Disease-Modifying Antirheumatic Drug Revenue and Market Share by Application (2019-2024)
2.5.3 Global Disease-Modifying Antirheumatic Drug Sale Price by Application (2019-2024)
3 GLOBAL DISEASE-MODIFYING ANTIRHEUMATIC DRUG BY COMPANY
3.1 Global Disease-Modifying Antirheumatic Drug Breakdown Data by Company
3.1.1 Global Disease-Modifying Antirheumatic Drug Annual Sales by Company (2019-2024)
3.1.2 Global Disease-Modifying Antirheumatic Drug Sales Market Share by Company (2019-2024)
3.2 Global Disease-Modifying Antirheumatic Drug Annual Revenue by Company (2019-2024)
3.2.1 Global Disease-Modifying Antirheumatic Drug Revenue by Company (2019-2024)
3.2.2 Global Disease-Modifying Antirheumatic Drug Revenue Market Share by Company (2019-2024)
3.3 Global Disease-Modifying Antirheumatic Drug Sale Price by Company
3.4 Key Manufacturers Disease-Modifying Antirheumatic Drug Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Disease-Modifying Antirheumatic Drug Product Location Distribution
3.4.2 Players Disease-Modifying Antirheumatic Drug Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR DISEASE-MODIFYING ANTIRHEUMATIC DRUG BY GEOGRAPHIC REGION
4.1 World Historic Disease-Modifying Antirheumatic Drug Market Size by Geographic Region (2019-2024)
4.1.1 Global Disease-Modifying Antirheumatic Drug Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Disease-Modifying Antirheumatic Drug Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Disease-Modifying Antirheumatic Drug Market Size by Country/Region (2019-2024)
4.2.1 Global Disease-Modifying Antirheumatic Drug Annual Sales by Country/Region (2019-2024)
4.2.2 Global Disease-Modifying Antirheumatic Drug Annual Revenue by Country/Region (2019-2024)
4.3 Americas Disease-Modifying Antirheumatic Drug Sales Growth
4.4 APAC Disease-Modifying Antirheumatic Drug Sales Growth
4.5 Europe Disease-Modifying Antirheumatic Drug Sales Growth
4.6 Middle East & Africa Disease-Modifying Antirheumatic Drug Sales Growth
5 AMERICAS
5.1 Americas Disease-Modifying Antirheumatic Drug Sales by Country
5.1.1 Americas Disease-Modifying Antirheumatic Drug Sales by Country (2019-2024)
5.1.2 Americas Disease-Modifying Antirheumatic Drug Revenue by Country (2019-2024)
5.2 Americas Disease-Modifying Antirheumatic Drug Sales by Type
5.3 Americas Disease-Modifying Antirheumatic Drug Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Disease-Modifying Antirheumatic Drug Sales by Region
6.1.1 APAC Disease-Modifying Antirheumatic Drug Sales by Region (2019-2024)
6.1.2 APAC Disease-Modifying Antirheumatic Drug Revenue by Region (2019-2024)
6.2 APAC Disease-Modifying Antirheumatic Drug Sales by Type
6.3 APAC Disease-Modifying Antirheumatic Drug Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Disease-Modifying Antirheumatic Drug by Country
7.1.1 Europe Disease-Modifying Antirheumatic Drug Sales by Country (2019-2024)
7.1.2 Europe Disease-Modifying Antirheumatic Drug Revenue by Country (2019-2024)
7.2 Europe Disease-Modifying Antirheumatic Drug Sales by Type
7.3 Europe Disease-Modifying Antirheumatic Drug Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Disease-Modifying Antirheumatic Drug by Country
8.1.1 Middle East & Africa Disease-Modifying Antirheumatic Drug Sales by Country (2019-2024)
8.1.2 Middle East & Africa Disease-Modifying Antirheumatic Drug Revenue by Country (2019-2024)
8.2 Middle East & Africa Disease-Modifying Antirheumatic Drug Sales by Type
8.3 Middle East & Africa Disease-Modifying Antirheumatic Drug Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Disease-Modifying Antirheumatic Drug
10.3 Manufacturing Process Analysis of Disease-Modifying Antirheumatic Drug
10.4 Industry Chain Structure of Disease-Modifying Antirheumatic Drug
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Disease-Modifying Antirheumatic Drug Distributors
11.3 Disease-Modifying Antirheumatic Drug Customer
12 WORLD FORECAST REVIEW FOR DISEASE-MODIFYING ANTIRHEUMATIC DRUG BY GEOGRAPHIC REGION
12.1 Global Disease-Modifying Antirheumatic Drug Market Size Forecast by Region
12.1.1 Global Disease-Modifying Antirheumatic Drug Forecast by Region (2025-2030)
12.1.2 Global Disease-Modifying Antirheumatic Drug Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Disease-Modifying Antirheumatic Drug Forecast by Type
12.7 Global Disease-Modifying Antirheumatic Drug Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 AbbVie
13.1.1 AbbVie Company Information
13.1.2 AbbVie Disease-Modifying Antirheumatic Drug Product Portfolios and Specifications
13.1.3 AbbVie Disease-Modifying Antirheumatic Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 AbbVie Main Business Overview
13.1.5 AbbVie Latest Developments
13.2 Amgen
13.2.1 Amgen Company Information
13.2.2 Amgen Disease-Modifying Antirheumatic Drug Product Portfolios and Specifications
13.2.3 Amgen Disease-Modifying Antirheumatic Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Amgen Main Business Overview
13.2.5 Amgen Latest Developments
13.3 Pfizer
13.3.1 Pfizer Company Information
13.3.2 Pfizer Disease-Modifying Antirheumatic Drug Product Portfolios and Specifications
13.3.3 Pfizer Disease-Modifying Antirheumatic Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Pfizer Main Business Overview
13.3.5 Pfizer Latest Developments
13.4 Roche Holding AG
13.4.1 Roche Holding AG Company Information
13.4.2 Roche Holding AG Disease-Modifying Antirheumatic Drug Product Portfolios and Specifications
13.4.3 Roche Holding AG Disease-Modifying Antirheumatic Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Roche Holding AG Main Business Overview
13.4.5 Roche Holding AG Latest Developments
13.5 Novartis International AG
13.5.1 Novartis International AG Company Information
13.5.2 Novartis International AG Disease-Modifying Antirheumatic Drug Product Portfolios and Specifications
13.5.3 Novartis International AG Disease-Modifying Antirheumatic Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Novartis International AG Main Business Overview
13.5.5 Novartis International AG Latest Developments
13.6 Johnson & Johnson
13.6.1 Johnson & Johnson Company Information
13.6.2 Johnson & Johnson Disease-Modifying Antirheumatic Drug Product Portfolios and Specifications
13.6.3 Johnson & Johnson Disease-Modifying Antirheumatic Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Johnson & Johnson Main Business Overview
13.6.5 Johnson & Johnson Latest Developments
13.7 Bristol-Myers Squibb
13.7.1 Bristol-Myers Squibb Company Information
13.7.2 Bristol-Myers Squibb Disease-Modifying Antirheumatic Drug Product Portfolios and Specifications
13.7.3 Bristol-Myers Squibb Disease-Modifying Antirheumatic Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 Bristol-Myers Squibb Main Business Overview
13.7.5 Bristol-Myers Squibb Latest Developments
13.8 Merck
13.8.1 Merck Company Information
13.8.2 Merck Disease-Modifying Antirheumatic Drug Product Portfolios and Specifications
13.8.3 Merck Disease-Modifying Antirheumatic Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 Merck Main Business Overview
13.8.5 Merck Latest Developments
13.9 UCB S.A.
13.9.1 UCB S.A. Company Information
13.9.2 UCB S.A. Disease-Modifying Antirheumatic Drug Product Portfolios and Specifications
13.9.3 UCB S.A. Disease-Modifying Antirheumatic Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 UCB S.A. Main Business Overview
13.9.5 UCB S.A. Latest Developments
13.10 Eli Lilly and Company
13.10.1 Eli Lilly and Company Company Information
13.10.2 Eli Lilly and Company Disease-Modifying Antirheumatic Drug Product Portfolios and Specifications
13.10.3 Eli Lilly and Company Disease-Modifying Antirheumatic Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.10.4 Eli Lilly and Company Main Business Overview
13.10.5 Eli Lilly and Company Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Disease-Modifying Antirheumatic Drug Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & ($ millions)
Table 2. Disease-Modifying Antirheumatic Drug Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions)
Table 3. Major Players of Non-Steroidal Anti-Inflammatory Drugs
Table 4. Major Players of Steroidal Anti-Inflammatory Drugs
Table 5. Major Players of Slow Acting Drug
Table 6. Major Players of Immunological Preparation
Table 7. Global Disease-Modifying Antirheumatic Drug Sales by Type (2019-2024) & (MT)
Table 8. Global Disease-Modifying Antirheumatic Drug Sales Market Share by Type (2019-2024)
Table 9. Global Disease-Modifying Antirheumatic Drug Revenue by Type (2019-2024) & ($ million)
Table 10. Global Disease-Modifying Antirheumatic Drug Revenue Market Share by Type (2019-2024)
Table 11. Global Disease-Modifying Antirheumatic Drug Sale Price by Type (2019-2024) & (USD/MT)
Table 12. Global Disease-Modifying Antirheumatic Drug Sales by Application (2019-2024) & (MT)
Table 13. Global Disease-Modifying Antirheumatic Drug Sales Market Share by Application (2019-2024)
Table 14. Global Disease-Modifying Antirheumatic Drug Revenue by Application (2019-2024)
Table 15. Global Disease-Modifying Antirheumatic Drug Revenue Market Share by Application (2019-2024)
Table 16. Global Disease-Modifying Antirheumatic Drug Sale Price by Application (2019-2024) & (USD/MT)
Table 17. Global Disease-Modifying Antirheumatic Drug Sales by Company (2019-2024) & (MT)
Table 18. Global Disease-Modifying Antirheumatic Drug Sales Market Share by Company (2019-2024)
Table 19. Global Disease-Modifying Antirheumatic Drug Revenue by Company (2019-2024) ($ Millions)
Table 20. Global Disease-Modifying Antirheumatic Drug Revenue Market Share by Company (2019-2024)
Table 21. Global Disease-Modifying Antirheumatic Drug Sale Price by Company (2019-2024) & (USD/MT)
Table 22. Key Manufacturers Disease-Modifying Antirheumatic Drug Producing Area Distribution and Sales Area
Table 23. Players Disease-Modifying Antirheumatic Drug Products Offered
Table 24. Disease-Modifying Antirheumatic Drug Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
Table 25. New Products and Potential Entrants
Table 26. Mergers & Acquisitions, Expansion
Table 27. Global Disease-Modifying Antirheumatic Drug Sales by Geographic Region (2019-2024) & (MT)
Table 28. Global Disease-Modifying Antirheumatic Drug Sales Market Share Geographic Region (2019-2024)
Table 29. Global Disease-Modifying Antirheumatic Drug Revenue by Geographic Region (2019-2024) & ($ millions)
Table 30. Global Disease-Modifying Antirheumatic Drug Revenue Market Share by Geographic Region (2019-2024)
Table 31. Global Disease-Modifying Antirheumatic Drug Sales by Country/Region (2019-2024) & (MT)
Table 32. Global Disease-Modifying Antirheumatic Drug Sales Market Share by Country/Region (2019-2024)
Table 33. Global Disease-Modifying Antirheumatic Drug Revenue by Country/Region (2019-2024) & ($ millions)
Table 34. Global Disease-Modifying Antirheumatic Drug Revenue Market Share by Country/Region (2019-2024)
Table 35. Americas Disease-Modifying Antirheumatic Drug Sales by Country (2019-2024) & (MT)
Table 36. Americas Disease-Modifying Antirheumatic Drug Sales Market Share by Country (2019-2024)
Table 37. Americas Disease-Modifying Antirheumatic Drug Revenue by Country (2019-2024) & ($ Millions)
Table 38. Americas Disease-Modifying Antirheumatic Drug Revenue Market Share by Country (2019-2024)
Table 39. Americas Disease-Modifying Antirheumatic Drug Sales by Type (2019-2024) & (MT)
Table 40. Americas Disease-Modifying Antirheumatic Drug Sales by Application (2019-2024) & (MT)
Table 41. APAC Disease-Modifying Antirheumatic Drug Sales by Region (2019-2024) & (MT)
Table 42. APAC Disease-Modifying Antirheumatic Drug Sales Market Share by Region (2019-2024)
Table 43. APAC Disease-Modifying Antirheumatic Drug Revenue by Region (2019-2024) & ($ Millions)
Table 44. APAC Disease-Modifying Antirheumatic Drug Revenue Market Share by Region (2019-2024)
Table 45. APAC Disease-Modifying Antirheumatic Drug Sales by Type (2019-2024) & (MT)
Table 46. APAC Disease-Modifying Antirheumatic Drug Sales by Application (2019-2024) & (MT)
Table 47. Europe Disease-Modifying Antirheumatic Drug Sales by Country (2019-2024) & (MT)
Table 48. Europe Disease-Modifying Antirheumatic Drug Sales Market Share by Country (2019-2024)
Table 49. Europe Disease-Modifying Antirheumatic Drug Revenue by Country (2019-2024) & ($ Millions)
Table 50. Europe Disease-Modifying Antirheumatic Drug Revenue Market Share by Country (2019-2024)
Table 51. Europe Disease-Modifying Antirheumatic Drug Sales by Type (2019-2024) & (MT)
Table 52. Europe Disease-Modifying Antirheumatic Drug Sales by Application (2019-2024) & (MT)
Table 53. Middle East & Africa Disease-Modifying Antirheumatic Drug Sales by Country (2019-2024) & (MT)
Table 54. Middle East & Africa Disease-Modifying Antirheumatic Drug Sales Market Share by Country (2019-2024)
Table 55. Middle East & Africa Disease-Modifying Antirheumatic Drug Revenue by Country (2019-2024) & ($ Millions)
Table 56. Middle East & Africa Disease-Modifying Antirheumatic Drug Revenue Market Share by Country (2019-2024)
Table 57. Middle East & Africa Disease-Modifying Antirheumatic Drug Sales by Type (2019-2024) & (MT)
Table 58. Middle East & Africa Disease-Modifying Antirheumatic Drug Sales by Application (2019-2024) & (MT)
Table 59. Key Market Drivers & Growth Opportunities of Disease-Modifying Antirheumatic Drug
Table 60. Key Market Challenges & Risks of Disease-Modifying Antirheumatic Drug
Table 61. Key Industry Trends of Disease-Modifying Antirheumatic Drug
Table 62. Disease-Modifying Antirheumatic Drug Raw Material
Table 63. Key Suppliers of Raw Materials
Table 64. Disease-Modifying Antirheumatic Drug Distributors List
Table 65. Disease-Modifying Antirheumatic Drug Customer List
Table 66. Global Disease-Modifying Antirheumatic Drug Sales Forecast by Region (2025-2030) & (MT)
Table 67. Global Disease-Modifying Antirheumatic Drug Revenue Forecast by Region (2025-2030) & ($ millions)
Table 68. Americas Disease-Modifying Antirheumatic Drug Sales Forecast by Country (2025-2030) & (MT)
Table 69. Americas Disease-Modifying Antirheumatic Drug Revenue Forecast by Country (2025-2030) & ($ millions)
Table 70. APAC Disease-Modifying Antirheumatic Drug Sales Forecast by Region (2025-2030) & (MT)
Table 71. APAC Disease-Modifying Antirheumatic Drug Revenue Forecast by Region (2025-2030) & ($ millions)
Table 72. Europe Disease-Modifying Antirheumatic Drug Sales Forecast by Country (2025-2030) & (MT)
Table 73. Europe Disease-Modifying Antirheumatic Drug Revenue Forecast by Country (2025-2030) & ($ millions)
Table 74. Middle East & Africa Disease-Modifying Antirheumatic Drug Sales Forecast by Country (2025-2030) & (MT)
Table 75. Middle East & Africa Disease-Modifying Antirheumatic Drug Revenue Forecast by Country (2025-2030) & ($ millions)
Table 76. Global Disease-Modifying Antirheumatic Drug Sales Forecast by Type (2025-2030) & (MT)
Table 77. Global Disease-Modifying Antirheumatic Drug Revenue Forecast by Type (2025-2030) & ($ Millions)
Table 78. Global Disease-Modifying Antirheumatic Drug Sales Forecast by Application (2025-2030) & (MT)
Table 79. Global Disease-Modifying Antirheumatic Drug Revenue Forecast by Application (2025-2030) & ($ Millions)
Table 80. AbbVie Basic Information, Disease-Modifying Antirheumatic Drug Manufacturing Base, Sales Area and Its Competitors
Table 81. AbbVie Disease-Modifying Antirheumatic Drug Product Portfolios and Specifications
Table 82. AbbVie Disease-Modifying Antirheumatic Drug Sales (MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 83. AbbVie Main Business
Table 84. AbbVie Latest Developments
Table 85. Amgen Basic Information, Disease-Modifying Antirheumatic Drug Manufacturing Base, Sales Area and Its Competitors
Table 86. Amgen Disease-Modifying Antirheumatic Drug Product Portfolios and Specifications
Table 87. Amgen Disease-Modifying Antirheumatic Drug Sales (MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 88. Amgen Main Business
Table 89. Amgen Latest Developments
Table 90. Pfizer Basic Information, Disease-Modifying Antirheumatic Drug Manufacturing Base, Sales Area and Its Competitors
Table 91. Pfizer Disease-Modifying Antirheumatic Drug Product Portfolios and Specifications
Table 92. Pfizer Disease-Modifying Antirheumatic Drug Sales (MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 93. Pfizer Main Business
Table 94. Pfizer Latest Developments
Table 95. Roche Holding AG Basic Information, Disease-Modifying Antirheumatic Drug Manufacturing Base, Sales Area and Its Competitors
Table 96. Roche Holding AG Disease-Modifying Antirheumatic Drug Product Portfolios and Specifications
Table 97. Roche Holding AG Disease-Modifying Antirheumatic Drug Sales (MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 98. Roche Holding AG Main Business
Table 99. Roche Holding AG Latest Developments
Table 100. Novartis International AG Basic Information, Disease-Modifying Antirheumatic Drug Manufacturing Base, Sales Area and Its Competitors
Table 101. Novartis International AG Disease-Modifying Antirheumatic Drug Product Portfolios and Specifications
Table 102. Novartis International AG Disease-Modifying Antirheumatic Drug Sales (MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 103. Novartis International AG Main Business
Table 104. Novartis International AG Latest Developments
Table 105. Johnson & Johnson Basic Information, Disease-Modifying Antirheumatic Drug Manufacturing Base, Sales Area and Its Competitors
Table 106. Johnson & Johnson Disease-Modifying Antirheumatic Drug Product Portfolios and Specifications
Table 107. Johnson & Johnson Disease-Modifying Antirheumatic Drug Sales (MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 108. Johnson & Johnson Main Business
Table 109. Johnson & Johnson Latest Developments
Table 110. Bristol-Myers Squibb Basic Information, Disease-Modifying Antirheumatic Drug Manufacturing Base, Sales Area and Its Competitors
Table 111. Bristol-Myers Squibb Disease-Modifying Antirheumatic Drug Product Portfolios and Specifications
Table 112. Bristol-Myers Squibb Disease-Modifying Antirheumatic Drug Sales (MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 113. Bristol-Myers Squibb Main Business
Table 114. Bristol-Myers Squibb Latest Developments
Table 115. Merck Basic Information, Disease-Modifying Antirheumatic Drug Manufacturing Base, Sales Area and Its Competitors
Table 116. Merck Disease-Modifying Antirheumatic Drug Product Portfolios and Specifications
Table 117. Merck Disease-Modifying Antirheumatic Drug Sales (MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 118. Merck Main Business
Table 119. Merck Latest Developments
Table 120. UCB S.A. Basic Information, Disease-Modifying Antirheumatic Drug Manufacturing Base, Sales Area and Its Competitors
Table 121. UCB S.A. Disease-Modifying Antirheumatic Drug Product Portfolios and Specifications
Table 122. UCB S.A. Disease-Modifying Antirheumatic Drug Sales (MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 123. UCB S.A. Main Business
Table 124. UCB S.A. Latest Developments
Table 125. Eli Lilly and Company Basic Information, Disease-Modifying Antirheumatic Drug Manufacturing Base, Sales Area and Its Competitors
Table 126. Eli Lilly and Company Disease-Modifying Antirheumatic Drug Product Portfolios and Specifications
Table 127. Eli Lilly and Company Disease-Modifying Antirheumatic Drug Sales (MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 128. Eli Lilly and Company Main Business
Table 129. Eli Lilly and Company Latest Developments
Table 1. Disease-Modifying Antirheumatic Drug Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & ($ millions)
Table 2. Disease-Modifying Antirheumatic Drug Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions)
Table 3. Major Players of Non-Steroidal Anti-Inflammatory Drugs
Table 4. Major Players of Steroidal Anti-Inflammatory Drugs
Table 5. Major Players of Slow Acting Drug
Table 6. Major Players of Immunological Preparation
Table 7. Global Disease-Modifying Antirheumatic Drug Sales by Type (2019-2024) & (MT)
Table 8. Global Disease-Modifying Antirheumatic Drug Sales Market Share by Type (2019-2024)
Table 9. Global Disease-Modifying Antirheumatic Drug Revenue by Type (2019-2024) & ($ million)
Table 10. Global Disease-Modifying Antirheumatic Drug Revenue Market Share by Type (2019-2024)
Table 11. Global Disease-Modifying Antirheumatic Drug Sale Price by Type (2019-2024) & (USD/MT)
Table 12. Global Disease-Modifying Antirheumatic Drug Sales by Application (2019-2024) & (MT)
Table 13. Global Disease-Modifying Antirheumatic Drug Sales Market Share by Application (2019-2024)
Table 14. Global Disease-Modifying Antirheumatic Drug Revenue by Application (2019-2024)
Table 15. Global Disease-Modifying Antirheumatic Drug Revenue Market Share by Application (2019-2024)
Table 16. Global Disease-Modifying Antirheumatic Drug Sale Price by Application (2019-2024) & (USD/MT)
Table 17. Global Disease-Modifying Antirheumatic Drug Sales by Company (2019-2024) & (MT)
Table 18. Global Disease-Modifying Antirheumatic Drug Sales Market Share by Company (2019-2024)
Table 19. Global Disease-Modifying Antirheumatic Drug Revenue by Company (2019-2024) ($ Millions)
Table 20. Global Disease-Modifying Antirheumatic Drug Revenue Market Share by Company (2019-2024)
Table 21. Global Disease-Modifying Antirheumatic Drug Sale Price by Company (2019-2024) & (USD/MT)
Table 22. Key Manufacturers Disease-Modifying Antirheumatic Drug Producing Area Distribution and Sales Area
Table 23. Players Disease-Modifying Antirheumatic Drug Products Offered
Table 24. Disease-Modifying Antirheumatic Drug Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
Table 25. New Products and Potential Entrants
Table 26. Mergers & Acquisitions, Expansion
Table 27. Global Disease-Modifying Antirheumatic Drug Sales by Geographic Region (2019-2024) & (MT)
Table 28. Global Disease-Modifying Antirheumatic Drug Sales Market Share Geographic Region (2019-2024)
Table 29. Global Disease-Modifying Antirheumatic Drug Revenue by Geographic Region (2019-2024) & ($ millions)
Table 30. Global Disease-Modifying Antirheumatic Drug Revenue Market Share by Geographic Region (2019-2024)
Table 31. Global Disease-Modifying Antirheumatic Drug Sales by Country/Region (2019-2024) & (MT)
Table 32. Global Disease-Modifying Antirheumatic Drug Sales Market Share by Country/Region (2019-2024)
Table 33. Global Disease-Modifying Antirheumatic Drug Revenue by Country/Region (2019-2024) & ($ millions)
Table 34. Global Disease-Modifying Antirheumatic Drug Revenue Market Share by Country/Region (2019-2024)
Table 35. Americas Disease-Modifying Antirheumatic Drug Sales by Country (2019-2024) & (MT)
Table 36. Americas Disease-Modifying Antirheumatic Drug Sales Market Share by Country (2019-2024)
Table 37. Americas Disease-Modifying Antirheumatic Drug Revenue by Country (2019-2024) & ($ Millions)
Table 38. Americas Disease-Modifying Antirheumatic Drug Revenue Market Share by Country (2019-2024)
Table 39. Americas Disease-Modifying Antirheumatic Drug Sales by Type (2019-2024) & (MT)
Table 40. Americas Disease-Modifying Antirheumatic Drug Sales by Application (2019-2024) & (MT)
Table 41. APAC Disease-Modifying Antirheumatic Drug Sales by Region (2019-2024) & (MT)
Table 42. APAC Disease-Modifying Antirheumatic Drug Sales Market Share by Region (2019-2024)
Table 43. APAC Disease-Modifying Antirheumatic Drug Revenue by Region (2019-2024) & ($ Millions)
Table 44. APAC Disease-Modifying Antirheumatic Drug Revenue Market Share by Region (2019-2024)
Table 45. APAC Disease-Modifying Antirheumatic Drug Sales by Type (2019-2024) & (MT)
Table 46. APAC Disease-Modifying Antirheumatic Drug Sales by Application (2019-2024) & (MT)
Table 47. Europe Disease-Modifying Antirheumatic Drug Sales by Country (2019-2024) & (MT)
Table 48. Europe Disease-Modifying Antirheumatic Drug Sales Market Share by Country (2019-2024)
Table 49. Europe Disease-Modifying Antirheumatic Drug Revenue by Country (2019-2024) & ($ Millions)
Table 50. Europe Disease-Modifying Antirheumatic Drug Revenue Market Share by Country (2019-2024)
Table 51. Europe Disease-Modifying Antirheumatic Drug Sales by Type (2019-2024) & (MT)
Table 52. Europe Disease-Modifying Antirheumatic Drug Sales by Application (2019-2024) & (MT)
Table 53. Middle East & Africa Disease-Modifying Antirheumatic Drug Sales by Country (2019-2024) & (MT)
Table 54. Middle East & Africa Disease-Modifying Antirheumatic Drug Sales Market Share by Country (2019-2024)
Table 55. Middle East & Africa Disease-Modifying Antirheumatic Drug Revenue by Country (2019-2024) & ($ Millions)
Table 56. Middle East & Africa Disease-Modifying Antirheumatic Drug Revenue Market Share by Country (2019-2024)
Table 57. Middle East & Africa Disease-Modifying Antirheumatic Drug Sales by Type (2019-2024) & (MT)
Table 58. Middle East & Africa Disease-Modifying Antirheumatic Drug Sales by Application (2019-2024) & (MT)
Table 59. Key Market Drivers & Growth Opportunities of Disease-Modifying Antirheumatic Drug
Table 60. Key Market Challenges & Risks of Disease-Modifying Antirheumatic Drug
Table 61. Key Industry Trends of Disease-Modifying Antirheumatic Drug
Table 62. Disease-Modifying Antirheumatic Drug Raw Material
Table 63. Key Suppliers of Raw Materials
Table 64. Disease-Modifying Antirheumatic Drug Distributors List
Table 65. Disease-Modifying Antirheumatic Drug Customer List
Table 66. Global Disease-Modifying Antirheumatic Drug Sales Forecast by Region (2025-2030) & (MT)
Table 67. Global Disease-Modifying Antirheumatic Drug Revenue Forecast by Region (2025-2030) & ($ millions)
Table 68. Americas Disease-Modifying Antirheumatic Drug Sales Forecast by Country (2025-2030) & (MT)
Table 69. Americas Disease-Modifying Antirheumatic Drug Revenue Forecast by Country (2025-2030) & ($ millions)
Table 70. APAC Disease-Modifying Antirheumatic Drug Sales Forecast by Region (2025-2030) & (MT)
Table 71. APAC Disease-Modifying Antirheumatic Drug Revenue Forecast by Region (2025-2030) & ($ millions)
Table 72. Europe Disease-Modifying Antirheumatic Drug Sales Forecast by Country (2025-2030) & (MT)
Table 73. Europe Disease-Modifying Antirheumatic Drug Revenue Forecast by Country (2025-2030) & ($ millions)
Table 74. Middle East & Africa Disease-Modifying Antirheumatic Drug Sales Forecast by Country (2025-2030) & (MT)
Table 75. Middle East & Africa Disease-Modifying Antirheumatic Drug Revenue Forecast by Country (2025-2030) & ($ millions)
Table 76. Global Disease-Modifying Antirheumatic Drug Sales Forecast by Type (2025-2030) & (MT)
Table 77. Global Disease-Modifying Antirheumatic Drug Revenue Forecast by Type (2025-2030) & ($ Millions)
Table 78. Global Disease-Modifying Antirheumatic Drug Sales Forecast by Application (2025-2030) & (MT)
Table 79. Global Disease-Modifying Antirheumatic Drug Revenue Forecast by Application (2025-2030) & ($ Millions)
Table 80. AbbVie Basic Information, Disease-Modifying Antirheumatic Drug Manufacturing Base, Sales Area and Its Competitors
Table 81. AbbVie Disease-Modifying Antirheumatic Drug Product Portfolios and Specifications
Table 82. AbbVie Disease-Modifying Antirheumatic Drug Sales (MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 83. AbbVie Main Business
Table 84. AbbVie Latest Developments
Table 85. Amgen Basic Information, Disease-Modifying Antirheumatic Drug Manufacturing Base, Sales Area and Its Competitors
Table 86. Amgen Disease-Modifying Antirheumatic Drug Product Portfolios and Specifications
Table 87. Amgen Disease-Modifying Antirheumatic Drug Sales (MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 88. Amgen Main Business
Table 89. Amgen Latest Developments
Table 90. Pfizer Basic Information, Disease-Modifying Antirheumatic Drug Manufacturing Base, Sales Area and Its Competitors
Table 91. Pfizer Disease-Modifying Antirheumatic Drug Product Portfolios and Specifications
Table 92. Pfizer Disease-Modifying Antirheumatic Drug Sales (MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 93. Pfizer Main Business
Table 94. Pfizer Latest Developments
Table 95. Roche Holding AG Basic Information, Disease-Modifying Antirheumatic Drug Manufacturing Base, Sales Area and Its Competitors
Table 96. Roche Holding AG Disease-Modifying Antirheumatic Drug Product Portfolios and Specifications
Table 97. Roche Holding AG Disease-Modifying Antirheumatic Drug Sales (MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 98. Roche Holding AG Main Business
Table 99. Roche Holding AG Latest Developments
Table 100. Novartis International AG Basic Information, Disease-Modifying Antirheumatic Drug Manufacturing Base, Sales Area and Its Competitors
Table 101. Novartis International AG Disease-Modifying Antirheumatic Drug Product Portfolios and Specifications
Table 102. Novartis International AG Disease-Modifying Antirheumatic Drug Sales (MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 103. Novartis International AG Main Business
Table 104. Novartis International AG Latest Developments
Table 105. Johnson & Johnson Basic Information, Disease-Modifying Antirheumatic Drug Manufacturing Base, Sales Area and Its Competitors
Table 106. Johnson & Johnson Disease-Modifying Antirheumatic Drug Product Portfolios and Specifications
Table 107. Johnson & Johnson Disease-Modifying Antirheumatic Drug Sales (MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 108. Johnson & Johnson Main Business
Table 109. Johnson & Johnson Latest Developments
Table 110. Bristol-Myers Squibb Basic Information, Disease-Modifying Antirheumatic Drug Manufacturing Base, Sales Area and Its Competitors
Table 111. Bristol-Myers Squibb Disease-Modifying Antirheumatic Drug Product Portfolios and Specifications
Table 112. Bristol-Myers Squibb Disease-Modifying Antirheumatic Drug Sales (MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 113. Bristol-Myers Squibb Main Business
Table 114. Bristol-Myers Squibb Latest Developments
Table 115. Merck Basic Information, Disease-Modifying Antirheumatic Drug Manufacturing Base, Sales Area and Its Competitors
Table 116. Merck Disease-Modifying Antirheumatic Drug Product Portfolios and Specifications
Table 117. Merck Disease-Modifying Antirheumatic Drug Sales (MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 118. Merck Main Business
Table 119. Merck Latest Developments
Table 120. UCB S.A. Basic Information, Disease-Modifying Antirheumatic Drug Manufacturing Base, Sales Area and Its Competitors
Table 121. UCB S.A. Disease-Modifying Antirheumatic Drug Product Portfolios and Specifications
Table 122. UCB S.A. Disease-Modifying Antirheumatic Drug Sales (MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 123. UCB S.A. Main Business
Table 124. UCB S.A. Latest Developments
Table 125. Eli Lilly and Company Basic Information, Disease-Modifying Antirheumatic Drug Manufacturing Base, Sales Area and Its Competitors
Table 126. Eli Lilly and Company Disease-Modifying Antirheumatic Drug Product Portfolios and Specifications
Table 127. Eli Lilly and Company Disease-Modifying Antirheumatic Drug Sales (MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 128. Eli Lilly and Company Main Business
Table 129. Eli Lilly and Company Latest Developments
LIST OF FIGURES
Figure 1. Picture of Disease-Modifying Antirheumatic Drug
Figure 2. Disease-Modifying Antirheumatic Drug Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Disease-Modifying Antirheumatic Drug Sales Growth Rate 2019-2030 (MT)
Figure 7. Global Disease-Modifying Antirheumatic Drug Revenue Growth Rate 2019-2030 ($ Millions)
Figure 8. Disease-Modifying Antirheumatic Drug Sales by Region (2019, 2023 & 2030) & ($ Millions)
Figure 9. Product Picture of Non-Steroidal Anti-Inflammatory Drugs
Figure 10. Product Picture of Steroidal Anti-Inflammatory Drugs
Figure 11. Product Picture of Slow Acting Drug
Figure 12. Product Picture of Immunological Preparation
Figure 13. Global Disease-Modifying Antirheumatic Drug Sales Market Share by Type in 2023
Figure 14. Global Disease-Modifying Antirheumatic Drug Revenue Market Share by Type (2019-2024)
Figure 15. Disease-Modifying Antirheumatic Drug Consumed in Pharmaceutical Industry
Figure 16. Global Disease-Modifying Antirheumatic Drug Market: Pharmaceutical Industry (2019-2024) & (MT)
Figure 17. Disease-Modifying Antirheumatic Drug Consumed in Hospital and Clinic
Figure 18. Global Disease-Modifying Antirheumatic Drug Market: Hospital and Clinic (2019-2024) & (MT)
Figure 19. Disease-Modifying Antirheumatic Drug Consumed in Other
Figure 20. Global Disease-Modifying Antirheumatic Drug Market: Other (2019-2024) & (MT)
Figure 21. Global Disease-Modifying Antirheumatic Drug Sales Market Share by Application (2023)
Figure 22. Global Disease-Modifying Antirheumatic Drug Revenue Market Share by Application in 2023
Figure 23. Disease-Modifying Antirheumatic Drug Sales Market by Company in 2023 (MT)
Figure 24. Global Disease-Modifying Antirheumatic Drug Sales Market Share by Company in 2023
Figure 25. Disease-Modifying Antirheumatic Drug Revenue Market by Company in 2023 ($ Million)
Figure 26. Global Disease-Modifying Antirheumatic Drug Revenue Market Share by Company in 2023
Figure 27. Global Disease-Modifying Antirheumatic Drug Sales Market Share by Geographic Region (2019-2024)
Figure 28. Global Disease-Modifying Antirheumatic Drug Revenue Market Share by Geographic Region in 2023
Figure 29. Americas Disease-Modifying Antirheumatic Drug Sales 2019-2024 (MT)
Figure 30. Americas Disease-Modifying Antirheumatic Drug Revenue 2019-2024 ($ Millions)
Figure 31. APAC Disease-Modifying Antirheumatic Drug Sales 2019-2024 (MT)
Figure 32. APAC Disease-Modifying Antirheumatic Drug Revenue 2019-2024 ($ Millions)
Figure 33. Europe Disease-Modifying Antirheumatic Drug Sales 2019-2024 (MT)
Figure 34. Europe Disease-Modifying Antirheumatic Drug Revenue 2019-2024 ($ Millions)
Figure 35. Middle East & Africa Disease-Modifying Antirheumatic Drug Sales 2019-2024 (MT)
Figure 36. Middle East & Africa Disease-Modifying Antirheumatic Drug Revenue 2019-2024 ($ Millions)
Figure 37. Americas Disease-Modifying Antirheumatic Drug Sales Market Share by Country in 2023
Figure 38. Americas Disease-Modifying Antirheumatic Drug Revenue Market Share by Country in 2023
Figure 39. Americas Disease-Modifying Antirheumatic Drug Sales Market Share by Type (2019-2024)
Figure 40. Americas Disease-Modifying Antirheumatic Drug Sales Market Share by Application (2019-2024)
Figure 41. United States Disease-Modifying Antirheumatic Drug Revenue Growth 2019-2024 ($ Millions)
Figure 42. Canada Disease-Modifying Antirheumatic Drug Revenue Growth 2019-2024 ($ Millions)
Figure 43. Mexico Disease-Modifying Antirheumatic Drug Revenue Growth 2019-2024 ($ Millions)
Figure 44. Brazil Disease-Modifying Antirheumatic Drug Revenue Growth 2019-2024 ($ Millions)
Figure 45. APAC Disease-Modifying Antirheumatic Drug Sales Market Share by Region in 2023
Figure 46. APAC Disease-Modifying Antirheumatic Drug Revenue Market Share by Regions in 2023
Figure 47. APAC Disease-Modifying Antirheumatic Drug Sales Market Share by Type (2019-2024)
Figure 48. APAC Disease-Modifying Antirheumatic Drug Sales Market Share by Application (2019-2024)
Figure 49. China Disease-Modifying Antirheumatic Drug Revenue Growth 2019-2024 ($ Millions)
Figure 50. Japan Disease-Modifying Antirheumatic Drug Revenue Growth 2019-2024 ($ Millions)
Figure 51. South Korea Disease-Modifying Antirheumatic Drug Revenue Growth 2019-2024 ($ Millions)
Figure 52. Southeast Asia Disease-Modifying Antirheumatic Drug Revenue Growth 2019-2024 ($ Millions)
Figure 53. India Disease-Modifying Antirheumatic Drug Revenue Growth 2019-2024 ($ Millions)
Figure 54. Australia Disease-Modifying Antirheumatic Drug Revenue Growth 2019-2024 ($ Millions)
Figure 55. China Taiwan Disease-Modifying Antirheumatic Drug Revenue Growth 2019-2024 ($ Millions)
Figure 56. Europe Disease-Modifying Antirheumatic Drug Sales Market Share by Country in 2023
Figure 57. Europe Disease-Modifying Antirheumatic Drug Revenue Market Share by Country in 2023
Figure 58. Europe Disease-Modifying Antirheumatic Drug Sales Market Share by Type (2019-2024)
Figure 59. Europe Disease-Modifying Antirheumatic Drug Sales Market Share by Application (2019-2024)
Figure 60. Germany Disease-Modifying Antirheumatic Drug Revenue Growth 2019-2024 ($ Millions)
Figure 61. France Disease-Modifying Antirheumatic Drug Revenue Growth 2019-2024 ($ Millions)
Figure 62. UK Disease-Modifying Antirheumatic Drug Revenue Growth 2019-2024 ($ Millions)
Figure 63. Italy Disease-Modifying Antirheumatic Drug Revenue Growth 2019-2024 ($ Millions)
Figure 64. Russia Disease-Modifying Antirheumatic Drug Revenue Growth 2019-2024 ($ Millions)
Figure 65. Middle East & Africa Disease-Modifying Antirheumatic Drug Sales Market Share by Country in 2023
Figure 66. Middle East & Africa Disease-Modifying Antirheumatic Drug Revenue Market Share by Country in 2023
Figure 67. Middle East & Africa Disease-Modifying Antirheumatic Drug Sales Market Share by Type (2019-2024)
Figure 68. Middle East & Africa Disease-Modifying Antirheumatic Drug Sales Market Share by Application (2019-2024)
Figure 69. Egypt Disease-Modifying Antirheumatic Drug Revenue Growth 2019-2024 ($ Millions)
Figure 70. South Africa Disease-Modifying Antirheumatic Drug Revenue Growth 2019-2024 ($ Millions)
Figure 71. Israel Disease-Modifying Antirheumatic Drug Revenue Growth 2019-2024 ($ Millions)
Figure 72. Turkey Disease-Modifying Antirheumatic Drug Revenue Growth 2019-2024 ($ Millions)
Figure 73. GCC Country Disease-Modifying Antirheumatic Drug Revenue Growth 2019-2024 ($ Millions)
Figure 74. Manufacturing Cost Structure Analysis of Disease-Modifying Antirheumatic Drug in 2023
Figure 75. Manufacturing Process Analysis of Disease-Modifying Antirheumatic Drug
Figure 76. Industry Chain Structure of Disease-Modifying Antirheumatic Drug
Figure 77. Channels of Distribution
Figure 78. Global Disease-Modifying Antirheumatic Drug Sales Market Forecast by Region (2025-2030)
Figure 79. Global Disease-Modifying Antirheumatic Drug Revenue Market Share Forecast by Region (2025-2030)
Figure 80. Global Disease-Modifying Antirheumatic Drug Sales Market Share Forecast by Type (2025-2030)
Figure 81. Global Disease-Modifying Antirheumatic Drug Revenue Market Share Forecast by Type (2025-2030)
Figure 82. Global Disease-Modifying Antirheumatic Drug Sales Market Share Forecast by Application (2025-2030)
Figure 83. Global Disease-Modifying Antirheumatic Drug Revenue Market Share Forecast by Application (2025-2030)
Figure 1. Picture of Disease-Modifying Antirheumatic Drug
Figure 2. Disease-Modifying Antirheumatic Drug Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Disease-Modifying Antirheumatic Drug Sales Growth Rate 2019-2030 (MT)
Figure 7. Global Disease-Modifying Antirheumatic Drug Revenue Growth Rate 2019-2030 ($ Millions)
Figure 8. Disease-Modifying Antirheumatic Drug Sales by Region (2019, 2023 & 2030) & ($ Millions)
Figure 9. Product Picture of Non-Steroidal Anti-Inflammatory Drugs
Figure 10. Product Picture of Steroidal Anti-Inflammatory Drugs
Figure 11. Product Picture of Slow Acting Drug
Figure 12. Product Picture of Immunological Preparation
Figure 13. Global Disease-Modifying Antirheumatic Drug Sales Market Share by Type in 2023
Figure 14. Global Disease-Modifying Antirheumatic Drug Revenue Market Share by Type (2019-2024)
Figure 15. Disease-Modifying Antirheumatic Drug Consumed in Pharmaceutical Industry
Figure 16. Global Disease-Modifying Antirheumatic Drug Market: Pharmaceutical Industry (2019-2024) & (MT)
Figure 17. Disease-Modifying Antirheumatic Drug Consumed in Hospital and Clinic
Figure 18. Global Disease-Modifying Antirheumatic Drug Market: Hospital and Clinic (2019-2024) & (MT)
Figure 19. Disease-Modifying Antirheumatic Drug Consumed in Other
Figure 20. Global Disease-Modifying Antirheumatic Drug Market: Other (2019-2024) & (MT)
Figure 21. Global Disease-Modifying Antirheumatic Drug Sales Market Share by Application (2023)
Figure 22. Global Disease-Modifying Antirheumatic Drug Revenue Market Share by Application in 2023
Figure 23. Disease-Modifying Antirheumatic Drug Sales Market by Company in 2023 (MT)
Figure 24. Global Disease-Modifying Antirheumatic Drug Sales Market Share by Company in 2023
Figure 25. Disease-Modifying Antirheumatic Drug Revenue Market by Company in 2023 ($ Million)
Figure 26. Global Disease-Modifying Antirheumatic Drug Revenue Market Share by Company in 2023
Figure 27. Global Disease-Modifying Antirheumatic Drug Sales Market Share by Geographic Region (2019-2024)
Figure 28. Global Disease-Modifying Antirheumatic Drug Revenue Market Share by Geographic Region in 2023
Figure 29. Americas Disease-Modifying Antirheumatic Drug Sales 2019-2024 (MT)
Figure 30. Americas Disease-Modifying Antirheumatic Drug Revenue 2019-2024 ($ Millions)
Figure 31. APAC Disease-Modifying Antirheumatic Drug Sales 2019-2024 (MT)
Figure 32. APAC Disease-Modifying Antirheumatic Drug Revenue 2019-2024 ($ Millions)
Figure 33. Europe Disease-Modifying Antirheumatic Drug Sales 2019-2024 (MT)
Figure 34. Europe Disease-Modifying Antirheumatic Drug Revenue 2019-2024 ($ Millions)
Figure 35. Middle East & Africa Disease-Modifying Antirheumatic Drug Sales 2019-2024 (MT)
Figure 36. Middle East & Africa Disease-Modifying Antirheumatic Drug Revenue 2019-2024 ($ Millions)
Figure 37. Americas Disease-Modifying Antirheumatic Drug Sales Market Share by Country in 2023
Figure 38. Americas Disease-Modifying Antirheumatic Drug Revenue Market Share by Country in 2023
Figure 39. Americas Disease-Modifying Antirheumatic Drug Sales Market Share by Type (2019-2024)
Figure 40. Americas Disease-Modifying Antirheumatic Drug Sales Market Share by Application (2019-2024)
Figure 41. United States Disease-Modifying Antirheumatic Drug Revenue Growth 2019-2024 ($ Millions)
Figure 42. Canada Disease-Modifying Antirheumatic Drug Revenue Growth 2019-2024 ($ Millions)
Figure 43. Mexico Disease-Modifying Antirheumatic Drug Revenue Growth 2019-2024 ($ Millions)
Figure 44. Brazil Disease-Modifying Antirheumatic Drug Revenue Growth 2019-2024 ($ Millions)
Figure 45. APAC Disease-Modifying Antirheumatic Drug Sales Market Share by Region in 2023
Figure 46. APAC Disease-Modifying Antirheumatic Drug Revenue Market Share by Regions in 2023
Figure 47. APAC Disease-Modifying Antirheumatic Drug Sales Market Share by Type (2019-2024)
Figure 48. APAC Disease-Modifying Antirheumatic Drug Sales Market Share by Application (2019-2024)
Figure 49. China Disease-Modifying Antirheumatic Drug Revenue Growth 2019-2024 ($ Millions)
Figure 50. Japan Disease-Modifying Antirheumatic Drug Revenue Growth 2019-2024 ($ Millions)
Figure 51. South Korea Disease-Modifying Antirheumatic Drug Revenue Growth 2019-2024 ($ Millions)
Figure 52. Southeast Asia Disease-Modifying Antirheumatic Drug Revenue Growth 2019-2024 ($ Millions)
Figure 53. India Disease-Modifying Antirheumatic Drug Revenue Growth 2019-2024 ($ Millions)
Figure 54. Australia Disease-Modifying Antirheumatic Drug Revenue Growth 2019-2024 ($ Millions)
Figure 55. China Taiwan Disease-Modifying Antirheumatic Drug Revenue Growth 2019-2024 ($ Millions)
Figure 56. Europe Disease-Modifying Antirheumatic Drug Sales Market Share by Country in 2023
Figure 57. Europe Disease-Modifying Antirheumatic Drug Revenue Market Share by Country in 2023
Figure 58. Europe Disease-Modifying Antirheumatic Drug Sales Market Share by Type (2019-2024)
Figure 59. Europe Disease-Modifying Antirheumatic Drug Sales Market Share by Application (2019-2024)
Figure 60. Germany Disease-Modifying Antirheumatic Drug Revenue Growth 2019-2024 ($ Millions)
Figure 61. France Disease-Modifying Antirheumatic Drug Revenue Growth 2019-2024 ($ Millions)
Figure 62. UK Disease-Modifying Antirheumatic Drug Revenue Growth 2019-2024 ($ Millions)
Figure 63. Italy Disease-Modifying Antirheumatic Drug Revenue Growth 2019-2024 ($ Millions)
Figure 64. Russia Disease-Modifying Antirheumatic Drug Revenue Growth 2019-2024 ($ Millions)
Figure 65. Middle East & Africa Disease-Modifying Antirheumatic Drug Sales Market Share by Country in 2023
Figure 66. Middle East & Africa Disease-Modifying Antirheumatic Drug Revenue Market Share by Country in 2023
Figure 67. Middle East & Africa Disease-Modifying Antirheumatic Drug Sales Market Share by Type (2019-2024)
Figure 68. Middle East & Africa Disease-Modifying Antirheumatic Drug Sales Market Share by Application (2019-2024)
Figure 69. Egypt Disease-Modifying Antirheumatic Drug Revenue Growth 2019-2024 ($ Millions)
Figure 70. South Africa Disease-Modifying Antirheumatic Drug Revenue Growth 2019-2024 ($ Millions)
Figure 71. Israel Disease-Modifying Antirheumatic Drug Revenue Growth 2019-2024 ($ Millions)
Figure 72. Turkey Disease-Modifying Antirheumatic Drug Revenue Growth 2019-2024 ($ Millions)
Figure 73. GCC Country Disease-Modifying Antirheumatic Drug Revenue Growth 2019-2024 ($ Millions)
Figure 74. Manufacturing Cost Structure Analysis of Disease-Modifying Antirheumatic Drug in 2023
Figure 75. Manufacturing Process Analysis of Disease-Modifying Antirheumatic Drug
Figure 76. Industry Chain Structure of Disease-Modifying Antirheumatic Drug
Figure 77. Channels of Distribution
Figure 78. Global Disease-Modifying Antirheumatic Drug Sales Market Forecast by Region (2025-2030)
Figure 79. Global Disease-Modifying Antirheumatic Drug Revenue Market Share Forecast by Region (2025-2030)
Figure 80. Global Disease-Modifying Antirheumatic Drug Sales Market Share Forecast by Type (2025-2030)
Figure 81. Global Disease-Modifying Antirheumatic Drug Revenue Market Share Forecast by Type (2025-2030)
Figure 82. Global Disease-Modifying Antirheumatic Drug Sales Market Share Forecast by Application (2025-2030)
Figure 83. Global Disease-Modifying Antirheumatic Drug Revenue Market Share Forecast by Application (2025-2030)
More Publications
Global Rifampicin Market Growth 2025-2031
US$ 3,660.00
October 2025
88 pages
Global Portable Veterinary X Ray System Market Growth 2024-2030
US$ 3,660.00
March 2024
114 pages
Global Cryogenic Storage Systems Market Growth 2024-2030
US$ 3,660.00
December 2024
109 pages
Global Mobility Wheelchairs Market Growth 2023-2029
US$ 3,660.00
March 2023
103 pages
Global Fibular Wedges Market Growth 2023-2029
US$ 3,660.00
March 2023
92 pages
